Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 599-608
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Table 2 Adverse events (AEs) observed with coronavirus disease 2019 vaccination in patients with solid tumors receiving systemic therapies
| Chemotherapy | Immunotherapy | Targeted therapy | |
| Patient number | 117 | 51 | 42 |
| Median age (yr) | 69 | 72 | 68 |
| Gender (Male/Female) | 55/62 | 29/22 | 18/24 |
| Type of vaccine administered(Moderna/Pfizer/J&J) | 47/65/5 | 23/24/4 | 19/21/2 |
| AEs (Grade 1 + 2), number (%) | 37 (60) | 18 (29) | 7 (11) |
| Therapy delayed because of AEs, # | 1 | 2 | 0 |
- Citation: Cox RE, Parish M, Oxencis C, Mckenna E, Thapa B, Chakrabarti S. Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy. World J Clin Oncol 2022; 13(7): 599-608
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/599.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.599